The recent outbreaks of infectious diseases caused by multidrug-resistant pathogens have
sounded a piercing alarm for the need of new effective antimicrobial agents to guard public …

Overuse of conventional antibiotics as well as the slow pace of new antibiotic drug
development leads to antimicrobial resistance (AMR). Because infections with multi‐drug …

Antimicrobial peptides (AMPs) are widespread in multicellular organisms. These structurally
diverse molecules are produced as the first line of defense against pathogens such as …

The increasing appearance of multidrug-resistant pathogens has created an urgent need for
suitable alternatives to current antibiotics. Antimicrobial peptides (AMPs), which act as …

More than 3000 antimicrobial peptides (AMPs) have been discovered, seven of which have
been approved by the US Food and Drug Administration (FDA). Now commercialized, these …

Antimicrobial peptides (AMPs) are pinpointed as promising molecules against antibiotic-
resistant bacterial infections. Nevertheless, there is a discrepancy between the AMP …

Infectious diseases continue to be one of the major contributors to human morbidity. The
rapid rate at which pathogenic microorganisms have developed resistance against frontline …

With the unprecedented rise of drug-resistant pathogens, particularly antibiotic-resistant
bacteria, and no new antibiotics in the pipeline over the last three decades, the issue of …

Rapid rise of antimicrobial resistance against conventional antimicrobials, resurgence of
multidrug resistant microbes and the slowdown in the development of new classes of …

Because the resistance of microorganisms to the available antibiotics is a growing
healthcare problem worldwide, the search for new antimicrobial peptides (AMPs) that …